Search clinical trials for: TEW-7197

Total 1946 results

MedPacto, Inc.
National OncoVenture

Completed

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

Advanced Stage Solid Tumors

United States
MedPacto, Inc.

Completed

Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

Myelodysplastic Syndromes

United States
MedPacto, Inc.

Completed

Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects

Healthy Volunteers

Korea, Republic of
Joon Oh Park

Recruiting

Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)

Metastatic Pancreatic Cancer

Korea, Republic of
MedPacto, Inc.

Active, not recruiting

TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer

Korea, Republic of
MedPacto, Inc.
AstraZeneca

Unknown

Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Non-Small Cell Lung Cancer Metastatic

Korea, Republic of
Samsung Medical Center

Not yet recruiting

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Gastric Cancer
Samsung Medical Center

Recruiting

Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Pancreas Cancer

Korea, Republic of
MedPacto, Inc.
AstraZeneca

Not yet recruiting

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Urothelial Carcinoma Recurrent | Advanced Urothelial Carcinoma

United States
Weill Medical College of Cornell University

Recruiting

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Myeloproliferative Neoplasm

United States
MedPacto, Inc.

Recruiting

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Osteosarcoma

United States, Korea, Republic of
Koen van Besien

Active, not recruiting

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
MedPacto, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Metastatic Colorectal Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Jennifer Eva Selfridge

Suspended

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States
Idience Co., Ltd.

Completed

Food Effect Study of IDX-1197 in Healthy Subjects

Healthy Male

Korea, Republic of
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria (EPP)

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
HeNan Sincere Biotech Co., Ltd

Recruiting

A Study of CL-197 Capsules in Healthy Participants

HIV-1

China
Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Mass Balance Study With MT-7117 (MT-7117 MB)

Healthy Volunteer

United Kingdom
National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Healthy Subjects

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

Spain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Idience Co., Ltd.
National OncoVenture; IlDong Pharmaceutical Co Ltd

Completed

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Healthy

United Kingdom
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Childhood Solid Neoplasm

United States, Canada
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Aramis Biosciences, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Daiichi Sankyo, Inc.
ICON Clinical Research; ArQule, Inc. (a wholly owned subsidiary of Merck Sharp...

Completed

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Solid Tumors

United States
Corporacion Parc Tauli

Completed

Efficiency of Two Dimensional High Definition vs Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery

Rectal Adenoma

Spain
MiNK Therapeutics

Completed

Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2

Respiratory Distress Syndrome, Adult

United States
Traslational Cancer Drugs Pharma, SL

Completed

Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Phase 2 Study in Patients With MiT Tumors

Renal Cell Carcinoma (RCC) | Alveolar Soft Part Sarcoma (ASPS) | Clear Cell Sarcoma (CCS)

United States, Canada, United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers

Healthy

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Kyowa Kirin Co., Ltd.

Completed

Study of ARQ 197 Monotherapy (ARQ 197-004)

Gastric Cancer

Japan, Korea, Republic of
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors (ARQ 197)

Cancer, Advanced Solid Tumors

United Kingdom
AbbVie

Completed

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Acute Kidney Injury

United States, Denmark
AbbVie

Terminated

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

Cardiothoracic Surgery | Vascular Surgery

United States, Denmark
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Cirrhosis

Spain, United States, Italy
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

ARQ 197 in Subjects With Metastatic Solid Tumors

Cancer | Tumor

United States
Amgen

Completed

A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate

Rheumatoid Arthritis
Kyowa Kirin Co., Ltd.

Completed

Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

Japan
Pepperdine University
University of California, Los Angeles

Completed

Evaluating New Mexico's Recidivism Reduction Program (RRP)

Behavior

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype

Healthy

United States
Daiichi Sankyo, Inc.

Terminated

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)

United States, France, United Kingdom
Daiichi Sankyo, Inc.
Medpace, Inc.

Completed

Effect of Tivantinib on the QTC Interval in Cancer Subjects

Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

Unresectable Hepatocellular Carcinoma

Belgium, Italy, United States, Germany, Canada

Search clinical trials for: TEW-7197

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations